The role of serotonin in the antidyskinetic effects of deep brain stimulation: Focus on antipsychotic-induced motor symptoms

Reviews in the Neurosciences

Volumn 24, Issue 2, 2013, Pages 153-166

  Creed, Meaghan C ^a,b   Nobrega, Jose N ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Catalepsy; Dopamine; Haloperidol; Highfrequency stimulation; Tardive dyskinesia

Indexed keywords

HALOPERIDOL; SEROTONIN;

ARTICLE; BASAL GANGLION; BRAIN DEPTH STIMULATION; CATALEPSY; DOPAMINERGIC NERVE CELL; FORCED SWIMMING TEST; GENE EXPRESSION; HUMAN; IMMEDIATE EARLY GENE; LEARNED HELPLESSNESS; LOCOMOTION; MOTOR ACTIVITY; NEUROTRANSMISSION; ONCOGENE C FOS; PARKINSONISM; PRIORITY JOURNAL; QUALITY OF LIFE; RIGIDITY; SEROTONINERGIC NERVE CELL; TARDIVE DYSKINESIA; THERAPY EFFECT;

EID: 84877941862     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2012-0083     Document Type: Article

References (140)

1. Alex, K.D. and Pehek, E.A. (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113, 296-320. (Pubitemid 46149046)
2. Appleby, B.S., Duggan, P.S., Regenberg, A., and Rabins, P.V. (2007). Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: a meta-analysis of ten years'experience. Mov. Disord. 22, 1722-1728. (Pubitemid 47597595)
3. Barker, E.L., Westphal, R.S., Schmidt, D., and Sanders-Bush, E. (1994). Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 269, 11687-11690.
4. Bekar, L., Libionka, W., Tian, G.F., Xu, Q., Torres, A., Wang, X., Lovatt, D., Williams, E., Takano, T., Schnermann, J., et al. (2008). Adenosine is crucial for deep brain stimulationmediated attenuation of tremor. Nat. Med. 14, 75-80.
5. Berney, A., Vingerhoets, F., Perrin, A., Guex, P., Villemure, J.G., Burkhard, P.R., Benkelfat, C., and Ghika, J. (2002). Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 59, 1427-1429. (Pubitemid 35286000)
6. Bigliani, V., Mulligan, R.S., Acton, P.D., Ohlsen, R.I., Pike, V.W., Ell, P.J., Gacinovic, S., Kerwin, R.W., and Pilowsky, L.S. (2000). Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I] epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl.) 150, 132-140. (Pubitemid 30429293)
7. Blanchet, P.J., Parent, M.T., Rompre, P.H., and Levesque, D. (2012). Relevance of animal models to human tardive dyskinesia. Behav. Brain Funct. 8, 1-9.
8. Burnet, P.W., Chen, C.P., McGowan, S., Franklin, M., and Harrison, P.J. (1996). The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73, 531-540. (Pubitemid 26168807)
9. Caley, C.F. (1998). Extrapyramidal reactions from concurrent SSRI and atypical antipsychotic use. Can. J. Psychiatry 43, 307-308. (Pubitemid 28524273)
10. Casey, D.E. (2004). Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry 65(Suppl 9), 25-28.
11. Chang, S.Y., Shon, Y.M., Agnesi, F., and Lee, K.H. (2009). Microthalamotomy effect during deep brain stimulation: potential involvement of adenosine and glutamate efflux. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2009, 3294-3297.
12. Chartoff, E.H., Ward, R.P., and Dorsa, D.M. (1999). Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidolinduced gene expression and catalepsy. J. Exp. Ther. 291, 531-537. (Pubitemid 29503521)
13. Christoffersen, C.L. and Meltzer, L.T. (1998). Reversal of haloperidolinduced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology 18, 399-402. (Pubitemid 28140666)
14. Cornea-Hebert, V., Riad, M., Wu, C., Singh, S.K., and Descarries, L. (1999). Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 409, 187-209. (Pubitemid 29264253)
15. Correll, C.U. and Schenk, E.M. (2008). Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 21, 151-156. (Pubitemid 351339869)
16. Creed-Carson, M., Oraha, A., and Nobrega, J.N. (2011). Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav. Brain Res. 219, 273-279.
17. Creed, M., Hamani, C., and Nobrega, J.N. (2011). Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Eur. Neuropsychopharmacol. 21, 393-400.
18. Creed, M.C., Hamani, C., Bridgman, A., Fletcher, P.J., and Nobrega, J.N. (2012a). Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei. J. Neurosci. 32, 9574-9581.
19. Creed, M.C., Hamani, C., and Nobrega, J.N. (2012b). Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: comparison with transient local inactivation. Eur. Neuropsychopharmacol. 22, 506-517.
20. Creed, M.C., Hamani, C., and Nobrega, J.N. (2012c). Effects of repeated deep brain stimulation on depressive-and anxiety-like behavior in rats: comparing entopeduncular and subthalamic nuclei. Brain Stimul. doi: 10.1016/j.brs.2012.09.012. Epub ahead of print.
21. D'Souza, D.C., Bennett, A., Abi-Dargham, A., and Krystal, J.H. (1994). Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient. J. Clin. Psychopharmacol. 14, 361-363. (Pubitemid 24316940)
22. Damier, P. (2009). Drug-induced dyskinesias. Curr. Opin. Neurol. 22, 394-399.
23. Damier, P., Thobois, S., Witjas, T., Cuny, E., Derost, P., Raoul, S., Mertens, P., Peragut, J.C., Lemaire, J.J., Burbaud, P., et al. (2007). Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch. Gen. Psychiatry 64, 170-176. (Pubitemid 46220774)
24. De Deurwaerdere, P., Navailles, S., Berg, K.A., Clarke, W.P., and Spampinato, U. (2004). Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 24, 3235-3241. (Pubitemid 38451889)
25. Degos, B., Deniau, J.M., Thierry, A.M., Glowinski, J., Pezard, L., and Maurice, N. (2005). Neuroleptic-induced catalepsy: electrophysiological mechanisms of functional recovery induced by high-frequency stimulation of the subthalamic nucleus. J. Neurosci. 25, 7687-7696. (Pubitemid 41170625)
26. Di Giovanni, G., De Deurwaerdere, P., Di Mascio, M., Di Matteo, V., Esposito, E., and Spampinato, U. (1999). Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91, 587-597. (Pubitemid 29193268)
27. Di Giovanni, G., Di Matteo, V., Pierucci, M., Benigno, A., and Esposito, E. (2006). Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies? Curr. Med. Chem. 13, 3069-3081. (Pubitemid 44509709)
28. Di Giovanni, G., Esposito, E., and Di Matteo, V. (2010). Role of serotonin in central dopamine dysfunction. CNS Neurosci. Ther. 16, 179-194.
29. Di Matteo, V., Di Giovanni, G., Di Mascio, M., and Esposito, E. (1999). SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38, 1195-1205. (Pubitemid 29292408)
30. Di Matteo, V., Pierucci, M., Esposito, E., Crescimanno, G., Benigno, A., and Di Giovanni, G. (2008). Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog. Brain Res. 172, 423-463.
31. Drapier, D., Drapier, S., Sauleau, P., Haegelen, C., Raoul, S., Biseul, I., Peron, J., Lallement, F., Rivier, I., Reymann, J.M., et al. (2006). Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J. Neurol. 253, 1083-1091. (Pubitemid 44441136)
32. Drapier, D., Peron, J., Leray, E., Sauleau, P., Biseul, I., Drapier, S., Le Jeune, F., Travers, D., Bourguignon, A., Haegelen, C., et al. (2008). Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson's disease have separate neural substrates. Neuropsychologia 46, 2796-2801.
33. Dray, A., Gonye, T.J., and Oakley, N.R. (1976a). Effects of alpha-flupenthixol on dopamine and 5-hydroxytryptamine responses of substantia nigra neurones. Neuropharmacology 15, 793-796. (Pubitemid 8005537)
34. Dray, A., Gonye, T.J., Oakley, N.R., and Tanner, T. (1976b). Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res. 113, 45-57.
35. Dubovsky, S.L. and Thomas, M. (1996). Tardive dyskinesia associated with fluoxetine. Psychiatr. Serv. 47, 991-993. (Pubitemid 26303424)
36. Eberle-Wang, K., Lucki, I., and Chesselet, M.F. (1996). A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72, 117-128.
37. Egan, M.F., Hurd, Y., Ferguson, J., Bachus, S.E., Hamid, E.H., and Hyde, T.M. (1996). Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology 127, 337-345. (Pubitemid 26356759)
38. Feuerstein, T.J., Kammerer, M., Lucking, C.H., and Moser, A. (2011). Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases. Naunyn Schmiedebergs Arch. Pharmacol. 384, 1-20.
39. Fletcher, P.J., Grottick, A.J., and Higgins, G.A. (2002). Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaineinduced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27, 576-586.
40. Fuxe, K. (1965). Evidence for the existence of monoamine neurons in the central nervous system. 3. The monoamine nerve terminal. Z. Zellforsch. Mikrosk. Anat. 65, 573-596.
41. Fuxe, K. and Hanson, C.F. (1967). Central catecholamine neurons and conditioned avoidance behaviour. Psychopharmacologia 11, 439-447.
42. Glazer, W.M. (2000). Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J. Clin. Psychiatry 61, 16-21. (Pubitemid 30155229)
43. Glazer, W.M. (2004). Olanzapine vs haloperidol for treatment of schizophrenia. J. Am. Med. Assoc. 291, 1064-1065; author reply 1065-1066.
44. Haddad, P.M. and Sharma, S.G. (2007). Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21, 911-936. (Pubitemid 47557106)
45. Haleem, D.J., Batool, F., Khan, N.H., Kamil, N., Ali, O., Saify, Z.S., and Haleem, M.A. (2002). Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med. Sci. Monit. 8, BR354-BR361.
46. Haleem, D.J., Shireen, E., and Haleem, M.A. (2004). Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 1323-1329. (Pubitemid 39592930)
47. Haleem, D.J., Samad, N., and Haleem, M.A. (2007). Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol. Biochem. Behav. 87, 115-121. (Pubitemid 46855825)
48. Hameleers, R., Blokland, A., Steinbusch, H.W., Visser-Vandewalle, V., and Temel, Y. (2007). Hypomobility after DOI administration can be reversed by subthalamic nucleus deep brain stimulation. Behav. Brain Res. 185, 65-67. (Pubitemid 47552576)
49. Harnack, D., Hamann, M., Meissner, W., Morgenstern, R., Kupsch, A., and Richter, A. (2004). High-frequency stimulation of the entopeduncular nucleus improves dystonia in dtsz hamsters. Neuroreport 15, 1391-1393. (Pubitemid 38925228)
50. Harnack, D., Meissner, W., Jira, J.A., Winter, C., Morgenstern, R., and Kupsch, A. (2008). Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. Exp. Neurol. 210, 257-260. (Pubitemid 351258073)
51. Hartung, H., Tan, S.K., Steinbusch, H.M., Temel, Y., and Sharp, T. (2011). High-frequency stimulation of the subthalamic nucleus inhibits the firing of juxtacellular labelled 5-HT-containing neurones. Neuroscience 186, 135-145.
52. Hicks, P.B. (1990). The effect of serotonergic agents on haloperidolinduced catalepsy. Life Sci. 47, 1609-1615.
53. Hornykiewicz, O. (1978). Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence. Neuroscience 3, 773-783. (Pubitemid 9029444)
54. Howland, R.H. (2011). Drug therapies for tardive dyskinesia: part 2. J. Psychosoc. Nurs. Ment. Health Serv. 49, 17-20.
55. Huang, X.F., Tan, Y.Y., Huang, X., and Wang, Q. (2007). Effect of chronic treatment with clozapine and haloperidol on 5-HT(2A and 2C) receptor mRNA expression in the rat brain. Neurosci. Res. 59, 314-321. (Pubitemid 47516602)
56. Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W.L., O'Laughlin, I.A., and Meltzer, H.Y. (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76, 1521-1531. (Pubitemid 32198256)
57. Ikram, H., Samad, N., and Haleem, D.J. (2007). Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Pak. J. Pharm. Sci. 20, 188-195.
58. Invernizzi, R.W., Cervo, L., and Samanin, R. (1988). 8-Hydroxy-2-(di-n- propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27, 515-518.
59. Johnson, M., Mitros, K., Stone, D.M., Zobrist, R., Hanson, G.R., and Gibb, J.W. (1992a). Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 261, 586-591.
60. Johnson, S.K., Wagner, G.C., and Fischer, H. (1992b). Neurochemical and motor effects of high dose haloperidol treatment: exacerbation by tryptophan supplementation. Proc. Soc. Exp. Biol. Med. 200, 571-575.
61. Kapur, S. (1996). 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 124, 35-39. (Pubitemid 26112772)
62. Kapur, S. and Remington, G. (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153, 466-476. (Pubitemid 26113309)
63. Kapur, S., Zipursky, R.B., and Remington, G. (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156, 286-293. (Pubitemid 29077120)
64. Kaur, S., Ozer, H., and Starr, M. (1997). MK 801 reverses haloperidolinduced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur. J. Pharmacol. 332, 153-160. (Pubitemid 27341919)
65. Kehne, J.H., Baron, B.M., Carr, A.A., Chaney, S.F., Elands, J., Feldman, D.J., Frank, R.A., van Giersbergen, P.L., McCloskey, T.C., Johnson, M.P., et al. (1996). Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277, 968-981.
66. Ketai, R. (1993). Interaction between fluoxetine and neuroleptics. Am. J. Psychiatry 150, 836-837.
67. Khan, A., Batool, F., and Haleem, D.J. (2001). Behavioral effects of 8-OH-DPAT in single and repeated haloperidol injected rats. Pak. J. Pharm. Sci. 14, 9-17.
68. Kostrzewa, R.M., Huang, N.Y., Kostrzewa, J.P., Nowak, P., and Brus, R. (2007). Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox. Res. 11, 41-50.
69. Lauterbach, E.C. and Shillcutt, S.D. (1997). Dyskinesia with fluoxetine: tardive or late-onset persistent, acute norfluoxetine dyskinesia? J. Clin. Psychiatry 58, 85-86. (Pubitemid 27106800)
70. Lucas, G. and Spampinato, U. (2000). Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74, 693-701. (Pubitemid 30053742)
71. Lucas, G., Bonhomme, N., De Deurwaerdere, P., Le Moal, M., and Spampinato, U. (1997). 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl.) 131, 57-63. (Pubitemid 27242855)
72. Marchese, G., Casu, M.A., Bartholini, F., Ruiu, S., Saba, P., Gessa, G.L., and Pani, L. (2002). Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to " early onset " vacuous chewing. Eur. J. Neurosci. 15, 1187-1196. (Pubitemid 35463619)
73. Marchese, G., Bartholini, F., Casu, M.A., Ruiu, S., Casti, P., Congeddu, E., Tambaro, S., and Pani, L. (2004). Haloperidol versus risperidone on rat " early onset " vacuous chewing. Behav. Brain Res. 149, 9-16. (Pubitemid 38096362)
74. Meissner, W., Harnack, D., Reese, R., Paul, G., Reum, T., Ansorge, M., Kusserow, H., Winter, C., Morgenstern, R., and Kupsch, A. (2003). High-frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats. J. Neurochem. 85, 601-609. (Pubitemid 36531923)
75. Meissner, W., Harnack, D., Hoessle, N., Bezard, E., Winter, C., Morgenstern, R., and Kupsch, A. (2004). High frequency stimulation of the entopeduncular nucleus has no effect on striatal dopaminergic transmission. Neurochem. Int. 44, 281-286. (Pubitemid 37340138)
76. Meltzer, H.Y. (1991). The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17, 263-287.
77. Meltzer, H.Y. and Nash, J.F. (1991). Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43, 587-604.
78. Meltzer, H.Y., Bastani, B., Ramirez, L., and Matsubara, S. (1989a). Clozapine: new research on efficacy and mechanism of action. Eur. Arch. Psychiatry Neurol. Sci. 238, 332-339. (Pubitemid 19184632)
79. Meltzer, H.Y., Matsubara, S., and Lee, J.C. (1989b). The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 25, 390-392. (Pubitemid 20260244)
80. Munkvad, I. (1975). The mechanism of action of psychopharmacological agents on behaviour. Acta Pharmacol. Toxicol. (Copenh.) 36, 21-30.
81. Naidu, P.S. and Kulkarni, S.K. (2001). Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur. J. Pharmacol. 428, 81-86. (Pubitemid 32971760)
82. Natesan, S., Reckless, G.E., Nobrega, J.N., Fletcher, P.J., and Kapur, S. (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31, 1854-1863.
83. Navailles, S. and De Deurwaerdere, P. (2012). Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. Mol. Neurobiol. 45, 173-185.
84. Navailles, S., De Deurwaerdere, P., and Spampinato, U. (2006). Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol. Psychiatry 59, 568-575. (Pubitemid 43320546)
85. Navailles, S., Benazzouz, A., Bioulac, B., Gross, C., and De Deurwaerdere, P. (2010). High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J. Neurosci. 30, 2356-2364.
86. Nedergaard, S., Bolam, J.P., and Greenfield, S.A. (1988). Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 333, 174-177.
87. Nedergaard, S., Flatman, J.A., and Engberg, I. (1991). Excitation of substantia nigra pars compacta neurones by 5-hydroxytryptamine in-vitro. Neuroreport 2, 329-332.
88. Ohno, Y., Shimizu, S., Imaki, J., Ishihara, S., Sofue, N., Sasa, M., and Kawai, Y. (2008). Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 55, 717-723.
89. Parent, A. (1981). Comparative anatomy of the serotoninergic systems. J. Physiol. (Paris) 77, 147-156. (Pubitemid 11032664)
90. Parent, M., Wallman, M.J., Gagnon, D., and Parent, A. (2011). Serotonin innervation of basal ganglia in monkeys and humans. J. Chem. Neuroanat. 41, 256-265.
91. Pazo, J.H., Hocht, C., Barcelo, A.C., Fillipini, B., and Lomastro, M.J. (2010). Effect of electrical and chemical stimulation of the subthalamic nucleus on the release of striatal dopamine. Synapse 64, 905-915.
92. Peluso, M.J., Lewis, S.W., Barnes, T.R., and Jones, P.B. (2012). Extrapyramidal motor side-effects of first-and secondgeneration antipsychotic drugs. Br. J. Psychiatry 200, 387-392.
93. Prinssen, E.P., Colpaert, F.C., and Koek, W. (2002). 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur. J. Pharmacol. 453, 217-221. (Pubitemid 35223513)
94. Randrup, A. and Munkvad, I. (1972). Influence of amphetamines on animal behaviour: stereotypy, functional impairment and possible animal-human correlations. Psychiatr. Neurol. Neurochir. 75, 193-202.
95. Randrup, A. and Munkvad, I. (1975). Stereotyped behavior. Pharmacol. Ther. B 1, 757-768.
96. Reavill, C., Taylor, S.G., Wood, M.D., Ashmeade, T., Austin, N.E., Avenell, K.Y., Boyfield, I., Branch, C.L., Cilia, J., Coldwell, M.C., et al. (2000). Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 294, 1154-1165. (Pubitemid 30666872)
97. Remington, G. (2007). Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr. Opin. Psychiatry 20, 131-137.
98. Robertson, G.S. and Fibiger, H.C. (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328.
99. Robertson, G.S., Matsumura, H., and Fibiger, H.C. (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271, 1058-1066. (Pubitemid 24377799)
100. Rosengarten, H., Bartoszyk, G.D., Quartermain, D., and Lin, Y. (2006). The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 273-279. (Pubitemid 43288066)
101. Samad, N., Khan, A., Perveen, T., Haider, S., Abdul Haleem, M., and Haleem, D.J. (2007). Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia. Acta Neurobiol. Exp. (Wars.) 67, 389-397.
102. Samad, N., Haleem, M.A., and Haleem, D.J. (2008). Behavioral effects of 1-(m-chlorophenyl)piperazine (m-CPP) in a rat model of tardive dyskinesia. Pak. J. Pharm. Sci. 21, 262-268.
103. Samanin, R. and Garattini, S. (1975). The serotonergic system in the brain and its possible functional connections with other aminergic systems. Life Sci. 17, 1201-1209.
104. Sandler, N.H. (1996). Tardive dyskinesia associated with fluoxetine. J. Clin. Psychiatry 57, 91.
105. Schmidt, W.J. and Bubser, M. (1989). Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav. 32, 621-623. (Pubitemid 19162378)
106. Schmidt, C.J., Sorensen, S.M., Kehne, J.H., Carr, A.A., and Palfreyman, M.G. (1995). The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 56, 2209-2222.
107. Schrag, A., Jahanshahi, M., and Quinn, N. (2000). What contributes to quality of life in patients with Parkinson's disease? J. Neurol. Neurosurg. Psychiatry 69, 308-312. (Pubitemid 30636233)
108. Sgambato-Faure, V. and Cenci, M.A. (2012). Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog. Neurobiol. 96, 69-86.
109. Shimizu, S., Tatara, A., Imaki, J., and Ohno, Y. (2010). Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 877-881.
110. Shireen, E., Qurratul, A., Batool, F., Saify, Z.S., and Haleem, D.J. (2002). Neurochemical effects of 8-hydroxy-2-di-n-propylamino tetralin in rats treated with haloperidol. Pak. J. Pharm. Sci. 15, 71-82.
111. Soares, K.V. and McGrath, J.J. (1999). The treatment of tardive dyskinesia -a systematic review and meta-analysis. Schizophr. Res. 39, 1-16; discussion 17-18. (Pubitemid 30074202)
112. Soares, K., McGrath, J., and Adams, C. (1996). Evidence and tardive dyskinesia. Lancet 347, 1696-1697.
113. Stahl, S.M. (1999). Introduction: what makes an antipsychotic atypical? J. Clin. Psychiatry 60 Suppl 10, 3-4. (Pubitemid 29237169)
114. Sun, B., Chen, S., Zhan, S., Le, W., and Krahl, S.E. (2007). Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochir. Suppl. 97, 207-214.
115. Takeshita, S., Kurisu, K., Trop, L., Arita, K., Akimitsu, T., and Verhoeff, N.P. (2005). Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems. Neurosurg. Rev. 28, 179-186; discussion 187. (Pubitemid 40909717)
116. Tamminga, C.A., Dale, J.M., Goodman, L., Kaneda, H., and Kaneda, N. (1990). Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl.) 102, 474-478. (Pubitemid 20379501)
117. Tan, S.K., Janssen, M.L., Jahanshahi, A., Chouliaras, L., Visser-Vandewalle, V., Lim, L.W., Steinbusch, H.W., Sharp, T., and Temel, Y. (2011). High frequency stimulation of the subthalamic nucleus increases c-fos immunoreactivity in the dorsal raphe nucleus and afferent brain regions. J. Psychiatr. Res. 45, 1307-1315.
118. Tan, S.K., Hartung, H., Visser-Vandewalle, V., Steinbusch, H.W., Temel, Y., and Sharp, T. (2012). A combined in vivo neurochemical and electrophysiological analysis of the effect of high-frequency stimulation of the subthalamic nucleus on 5-HT transmission. Exp. Neurol. 233, 145-153.
119. Tawfik, V.L., Chang, S.Y., Hitti, F.L., Roberts, D.W., Leiter, J.C., Jovanovic, S., and Lee, K.H. (2010). Deep brain stimulation results in local glutamate and adenosine release: investigation into the role of astrocytes. Neurosurgery 67, 367-375.
120. Temel, Y., Kessels, A., Tan, S., Topdag, A., Boon P., and Visser-Vandewalle, V. (2006). Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat. Disord. 12, 265-272. (Pubitemid 43816341)
121. Temel, Y., Boothman, L.J., Blokland, A., Magill, P.J., Steinbusch, H.W., Visser-Vandewalle, V., and Sharp, T. (2007). Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc. Natl. Acad. Sci. USA 104, 17087-17092. (Pubitemid 350210996)
122. Thobois, S., Poisson, A., and Damier, P. (2011). Surgery for tardive dyskinesia. Int. Rev. Neurobiol. 98, 289-296.
123. Tommasi, G., Lanotte, M., Albert, U., Zibetti, M., Castelli, L., Maina, G., and Lopiano, L. (2008). Transient acute depressive state induced by subthalamic region stimulation. J. Neurol. Sci 273, 135-138.
124. Travis, M.J., Busatto, G.F., Pilowsky, L.S., Kerwin, R.W., Mulligan, R., Gacinovic, S., Costa, D.C., Ell, P.J., Mertens, J., and Terriere, D. (1997). Serotonin: 5-HT2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole. Br. J. Psychiatry 171, 290-291. (Pubitemid 27400308)
125. Troster, A.I., Fields, J.A., Wilkinson, S., Pahwa, R., Koller, W.C., and Lyons, K.E. (2003). Effect of motor improvement on quality of life following subthalamic stimulation is mediated by changes in depressive symptomatology. Stereotact. Funct. Neurosurg. 80, 43-47. (Pubitemid 38182743)
126. Turrone, P., Remington, G., and Nobrega, J.N. (2002). The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci. Biobehav. Rev. 26, 361-380. (Pubitemid 34553319)
127. Turrone, P., Remington, G., Kapur, S., and Nobrega, J.N. (2003). Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology 28, 1433-1439. (Pubitemid 41070877)
128. Ulla, M., Thobois, S., Llorca, P.M., Derost, P., Lemaire, J.J., Chereau-Boudet, I., de Chazeron, I., Schmitt, A., Ballanger, B., Broussolle, E., et al. (2011). Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson's disease: clinical, anatomical and functional imaging study. J. Neurol. Neurosurg. Psychiatry 82, 607-614.
129. van Dijk, A., Klompmakers, A.A., Feenstra, M.G., and Denys, D. (2012). Deep brain stimulation of the accumbens increases dopamine, serotonin and noradrenaline in the prefrontal cortex. J. Neurochem. 123, 897-903.
130. van Harten, P.N. and Tenback, D.E. (2011). Tardive dyskinesia: clinical presentation and treatment. Int. Rev. Neurobiol. 98, 187-210.
131. Voon, V., Krack, P., Lang, A.E., Lozano, A.M., Dujardin, K., Schupbach, M., D'Ambrosia, J., Thobois, S., Tamma, F., Herzog, J., et al. (2008). A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 131, 2720-2728.
132. Wadenberg, M.L. (1996). Serotonergic mechanisms in neurolepticinduced catalepsy in the rat. Neurosci. Biobehav. Rev. 20, 325-339.
133. Wadenberg, M.L., Soliman, A., VanderSpek, S.C., and Kapur, S. (2001). Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25, 633-641. (Pubitemid 32995945)
134. Wallman, M.J., Gagnon, D., and Parent, M. (2011). Serotonin innervation of human basal ganglia. Eur J. Neurosci. 33, 1519-1532.
135. Welter, M.L., Grabli, D., and Vidailhet, M. (2010). Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Curr. Opin. Neurol. 23, 420-425.
136. Wiecki, T.V., Riedinger, K., von Ameln-Mayerhofer, A., Schmidt, W.J., and Frank, M.J. (2009). A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal. Psychopharmacology 204, 265-277.
137. Willins, D.L., Deutch, A.Y., and Roth, B.L. (1997). Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27, 79-82. (Pubitemid 27327604)
138. Wolf, W.A., Bieganski, G.J., Guillen, V., and Mignon, L. (2005). Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced " early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology (Berl.) 182, 84-94. (Pubitemid 41400865)
139. Yamawaki, N., Magill, P.J., Woodhall, G.L., Hall, S.D., and Stanford, I.M. (2012). Frequency selectivity and dopamine-dependence of plasticity at glutamatergic synapses in the subthalamic nucleus. Neuroscience 203, 1-11.
140. Zhang, B., Chu, J., Zhang, J., and Ma, Y. (2008). Change of extracellular glutamate and gamma-aminobutyric acid in substantia nigra and globus pallidus during electrical stimulation of subthalamic nucleus in epileptic rats. Stereotact. Funct. Neurosurg. 86, 208-215. (Pubitemid 351951486)